The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
about
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers.Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3.Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients.[Clinical investigation of efficacy of third-line and beyond pemetrexed treatment in advanced non-squamous non-small cell lung cancer].
P2860
The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
@ast
The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
@en
type
label
The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
@ast
The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
@en
prefLabel
The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
@ast
The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
@en
P356
P1433
P1476
The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
@en
P2093
Alex A Adjei
Julian R Molina
P356
10.3816/CLC.2003.N.017
P407
P577
2003-07-01T00:00:00Z